Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation

Chi Jung Huang, Shih Hung Huang, Chih Cheng Chien, Henry Hsin Chung Lee, Shung Haur Yang, Chun Chao Chang, Chia Long Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

KRAS and BRAF mutations are frequently detected in cases of colorectal cancer (CRC). The microsatellite status of patients with CRC and mutated KRAS/BRAF is important when determining cancer therapy. In the present study, the microsatellite status and genetic polymorphisms of KRAS (codons 12 and 13) and BRAF (V600E) were characterized in CRC tissue. The mismatch repair activity and oncogenic potential of KRAS were assessed by immunoblots from two KRAS-mutated CRC cell lines, SW480 and HCT116, with different microsatellite statuses, following treatment with 5-fluorouracil (5-FU) and oxaliplatin. Of all the 205 patients with CRC enrolled in the present study, 31.2% (64 of 205) had a KRAS or BRAF mutation, and 79.7% (51 of 64) of these patients with a KRAS/BRAF mutation exhibited microsatellite stability (MSS), indicating that microsatellite status is correlated with KRAS/BRAF mutation (P=0.027). A higher proportion (39.0%, 41 of 105) of elderly patients (≥62.6 years) had mutated KRAS or BRAF than younger patients (<62.6 years; 23.0%, 23 of 100; P=0.013). In the subgroup of 154 patients with MSS, patients without the KRAS or BRAF mutation (n=110) had longer disease-specific survival rates (58.8±9.4%) than patients with KRAS or BRAF mutations (n=44; 50.6±11.0%; P=0.043). Cytoplasmic KRAS levels decreased whereas nuclear MutS protein homolog 2 (MSH2) levels increased slightly in CRC HCT116 cells that were microsatellite instable, following treatment with 76.9 μM 5-FU for 2 days. In microsatellite stable SW480 cells, MSH2 levels markedly increased in the nucleus following 150 μM oxaliplatin treatment for 3 days. However, no significant change was observed regarding KRAS distribution in these cells. The results of the present study suggest that it is important to identify patients with CRC who may benefit from adjuvant chemotherapy with 5-FU or oxaliplatin, particularly CRC patients with MSS and mutated KRAS or BRAF, who have poorer overall survival rates than patients with microsatellite instability. Knowledge of the microsatellite status of patients and whether they harbor KRAS or BRAF mutations may enable more effective therapeutic strategies to be developed. Further prospective studies are required to validate the findings of the current study.

Original languageEnglish
Pages (from-to)4427-4434
Number of pages8
JournalOncology Letters
Volume12
Issue number6
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Microsatellite Repeats
Colorectal Neoplasms
Drug Therapy
Mutation
oxaliplatin
Fluorouracil
MutS Homolog 2 Protein
Survival Rate
HCT116 Cells
Therapeutics
Microsatellite Instability
DNA Mismatch Repair
Genetic Polymorphisms
Adjuvant Chemotherapy
Nuclear Proteins
Codon
Prospective Studies
Cell Line

Keywords

  • 5-fluorouracil
  • BRAF
  • Colorectal cancer
  • DNA mismatch repair
  • KRAS
  • Microsatellite status
  • Oxaliplatin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation. / Huang, Chi Jung; Huang, Shih Hung; Chien, Chih Cheng; Lee, Henry Hsin Chung; Yang, Shung Haur; Chang, Chun Chao; Lee, Chia Long.

In: Oncology Letters, Vol. 12, No. 6, 01.12.2016, p. 4427-4434.

Research output: Contribution to journalArticle

Huang, Chi Jung ; Huang, Shih Hung ; Chien, Chih Cheng ; Lee, Henry Hsin Chung ; Yang, Shung Haur ; Chang, Chun Chao ; Lee, Chia Long. / Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation. In: Oncology Letters. 2016 ; Vol. 12, No. 6. pp. 4427-4434.
@article{1bcb5cd09ed1453b95c46f167c4d29b9,
title = "Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation",
abstract = "KRAS and BRAF mutations are frequently detected in cases of colorectal cancer (CRC). The microsatellite status of patients with CRC and mutated KRAS/BRAF is important when determining cancer therapy. In the present study, the microsatellite status and genetic polymorphisms of KRAS (codons 12 and 13) and BRAF (V600E) were characterized in CRC tissue. The mismatch repair activity and oncogenic potential of KRAS were assessed by immunoblots from two KRAS-mutated CRC cell lines, SW480 and HCT116, with different microsatellite statuses, following treatment with 5-fluorouracil (5-FU) and oxaliplatin. Of all the 205 patients with CRC enrolled in the present study, 31.2{\%} (64 of 205) had a KRAS or BRAF mutation, and 79.7{\%} (51 of 64) of these patients with a KRAS/BRAF mutation exhibited microsatellite stability (MSS), indicating that microsatellite status is correlated with KRAS/BRAF mutation (P=0.027). A higher proportion (39.0{\%}, 41 of 105) of elderly patients (≥62.6 years) had mutated KRAS or BRAF than younger patients (<62.6 years; 23.0{\%}, 23 of 100; P=0.013). In the subgroup of 154 patients with MSS, patients without the KRAS or BRAF mutation (n=110) had longer disease-specific survival rates (58.8±9.4{\%}) than patients with KRAS or BRAF mutations (n=44; 50.6±11.0{\%}; P=0.043). Cytoplasmic KRAS levels decreased whereas nuclear MutS protein homolog 2 (MSH2) levels increased slightly in CRC HCT116 cells that were microsatellite instable, following treatment with 76.9 μM 5-FU for 2 days. In microsatellite stable SW480 cells, MSH2 levels markedly increased in the nucleus following 150 μM oxaliplatin treatment for 3 days. However, no significant change was observed regarding KRAS distribution in these cells. The results of the present study suggest that it is important to identify patients with CRC who may benefit from adjuvant chemotherapy with 5-FU or oxaliplatin, particularly CRC patients with MSS and mutated KRAS or BRAF, who have poorer overall survival rates than patients with microsatellite instability. Knowledge of the microsatellite status of patients and whether they harbor KRAS or BRAF mutations may enable more effective therapeutic strategies to be developed. Further prospective studies are required to validate the findings of the current study.",
keywords = "5-fluorouracil, BRAF, Colorectal cancer, DNA mismatch repair, KRAS, Microsatellite status, Oxaliplatin",
author = "Huang, {Chi Jung} and Huang, {Shih Hung} and Chien, {Chih Cheng} and Lee, {Henry Hsin Chung} and Yang, {Shung Haur} and Chang, {Chun Chao} and Lee, {Chia Long}",
year = "2016",
month = "12",
day = "1",
doi = "10.3892/ol.2016.5275",
language = "English",
volume = "12",
pages = "4427--4434",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation

AU - Huang, Chi Jung

AU - Huang, Shih Hung

AU - Chien, Chih Cheng

AU - Lee, Henry Hsin Chung

AU - Yang, Shung Haur

AU - Chang, Chun Chao

AU - Lee, Chia Long

PY - 2016/12/1

Y1 - 2016/12/1

N2 - KRAS and BRAF mutations are frequently detected in cases of colorectal cancer (CRC). The microsatellite status of patients with CRC and mutated KRAS/BRAF is important when determining cancer therapy. In the present study, the microsatellite status and genetic polymorphisms of KRAS (codons 12 and 13) and BRAF (V600E) were characterized in CRC tissue. The mismatch repair activity and oncogenic potential of KRAS were assessed by immunoblots from two KRAS-mutated CRC cell lines, SW480 and HCT116, with different microsatellite statuses, following treatment with 5-fluorouracil (5-FU) and oxaliplatin. Of all the 205 patients with CRC enrolled in the present study, 31.2% (64 of 205) had a KRAS or BRAF mutation, and 79.7% (51 of 64) of these patients with a KRAS/BRAF mutation exhibited microsatellite stability (MSS), indicating that microsatellite status is correlated with KRAS/BRAF mutation (P=0.027). A higher proportion (39.0%, 41 of 105) of elderly patients (≥62.6 years) had mutated KRAS or BRAF than younger patients (<62.6 years; 23.0%, 23 of 100; P=0.013). In the subgroup of 154 patients with MSS, patients without the KRAS or BRAF mutation (n=110) had longer disease-specific survival rates (58.8±9.4%) than patients with KRAS or BRAF mutations (n=44; 50.6±11.0%; P=0.043). Cytoplasmic KRAS levels decreased whereas nuclear MutS protein homolog 2 (MSH2) levels increased slightly in CRC HCT116 cells that were microsatellite instable, following treatment with 76.9 μM 5-FU for 2 days. In microsatellite stable SW480 cells, MSH2 levels markedly increased in the nucleus following 150 μM oxaliplatin treatment for 3 days. However, no significant change was observed regarding KRAS distribution in these cells. The results of the present study suggest that it is important to identify patients with CRC who may benefit from adjuvant chemotherapy with 5-FU or oxaliplatin, particularly CRC patients with MSS and mutated KRAS or BRAF, who have poorer overall survival rates than patients with microsatellite instability. Knowledge of the microsatellite status of patients and whether they harbor KRAS or BRAF mutations may enable more effective therapeutic strategies to be developed. Further prospective studies are required to validate the findings of the current study.

AB - KRAS and BRAF mutations are frequently detected in cases of colorectal cancer (CRC). The microsatellite status of patients with CRC and mutated KRAS/BRAF is important when determining cancer therapy. In the present study, the microsatellite status and genetic polymorphisms of KRAS (codons 12 and 13) and BRAF (V600E) were characterized in CRC tissue. The mismatch repair activity and oncogenic potential of KRAS were assessed by immunoblots from two KRAS-mutated CRC cell lines, SW480 and HCT116, with different microsatellite statuses, following treatment with 5-fluorouracil (5-FU) and oxaliplatin. Of all the 205 patients with CRC enrolled in the present study, 31.2% (64 of 205) had a KRAS or BRAF mutation, and 79.7% (51 of 64) of these patients with a KRAS/BRAF mutation exhibited microsatellite stability (MSS), indicating that microsatellite status is correlated with KRAS/BRAF mutation (P=0.027). A higher proportion (39.0%, 41 of 105) of elderly patients (≥62.6 years) had mutated KRAS or BRAF than younger patients (<62.6 years; 23.0%, 23 of 100; P=0.013). In the subgroup of 154 patients with MSS, patients without the KRAS or BRAF mutation (n=110) had longer disease-specific survival rates (58.8±9.4%) than patients with KRAS or BRAF mutations (n=44; 50.6±11.0%; P=0.043). Cytoplasmic KRAS levels decreased whereas nuclear MutS protein homolog 2 (MSH2) levels increased slightly in CRC HCT116 cells that were microsatellite instable, following treatment with 76.9 μM 5-FU for 2 days. In microsatellite stable SW480 cells, MSH2 levels markedly increased in the nucleus following 150 μM oxaliplatin treatment for 3 days. However, no significant change was observed regarding KRAS distribution in these cells. The results of the present study suggest that it is important to identify patients with CRC who may benefit from adjuvant chemotherapy with 5-FU or oxaliplatin, particularly CRC patients with MSS and mutated KRAS or BRAF, who have poorer overall survival rates than patients with microsatellite instability. Knowledge of the microsatellite status of patients and whether they harbor KRAS or BRAF mutations may enable more effective therapeutic strategies to be developed. Further prospective studies are required to validate the findings of the current study.

KW - 5-fluorouracil

KW - BRAF

KW - Colorectal cancer

KW - DNA mismatch repair

KW - KRAS

KW - Microsatellite status

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=84995752431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995752431&partnerID=8YFLogxK

U2 - 10.3892/ol.2016.5275

DO - 10.3892/ol.2016.5275

M3 - Article

VL - 12

SP - 4427

EP - 4434

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 6

ER -